Compare MGM Resorts International (MGM) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? MGM Resorts International trades at $28.73 (market cap $7.40B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: MGM Resorts International is far larger — about 7.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and MGM Resorts International pays a 0.03% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 92 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MGM | MRVI | |
|---|---|---|
Market Cap | $7.40B | $972.90M |
Volume | 3,687,296 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $9.00 |
52-Week Low | $28.96 | $2.83 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $34.70B | $1.08B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $28.96, down 1.23% amid recent volatility following the collapse of Barry Diller's $48.30 per share acquisition offer. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal mixed results with Q2 2026 EPS beating expectations but net margins declining to 2.4%. Recent news highlights ongoing M&A discussions, including potential MGM bids for People Inc., creating uncertainty around strategic direction.
Despite near-term headwinds, MGM maintains strong analyst support with 51% buy ratings and a $47.57 consensus target representing 64% upside. Key risks include execution on acquisition strategy, declining profitability margins, and high debt levels. The current valuation at 17.8x P/E appears reasonable if management can stabilize earnings and navigate the evolving casino landscape effectively.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
